This June, GC Biotech will participate in two major industry exhibitions in China, bringing together the latest innovations in veterinary drugs, vaccine adjuvants, and pharmaceutical technologies. These events provide an important platform for global collaboration, technological exchange, and industry advancement.

We sincerely invite partners and industry professionals to visit us, explore new trends, and discover innovative solutions shaping the future of biopharmaceutical development.

First Stop: China Veterinary Drugs Exhibition

Low-Cost, High-Efficiency Veterinary Solutions

Event: The 11th China Veterinary Drugs Exhibition
Date: June 18–19
Venue: Nanchang Greenland International Expo Center
Booth: A4-131

Exhibition Highlights

1. Breakthrough Cost-Effective Adjuvant Technology

GC Biotech will showcase its globally introduced Quillaja saponaria-derived veterinary saponin adjuvant, designed to significantly reduce vaccine production costs.

• Cost per dose: less than RMB 0.05
• Enhances vaccine immune performance
• Supports large-scale veterinary vaccine production

This innovation provides a powerful balance between cost reduction and immune efficacy improvement.

2. Comprehensive Application Solutions

At the exhibition, we will present multiple novel adjuvant formulations developed across three major technology platforms, covering a wide range of animal vaccine applications.

These solutions are designed to meet diverse development needs across veterinary medicine, enabling more efficient and targeted vaccine design.

3. Customized Technical Support

Our technical experts will be available on-site to provide:

• Tailored vaccine enhancement strategies
• Integrated adjuvant solution design
• Support for both traditional and next-generation vaccine development

Second Stop: PMEC China 2025

Precision Adjuvant Innovation for Human Vaccines

Event: CPHI & PMEC China 2025
Date: June 24–26
Venue: Shanghai New International Expo Center (Pudong)
Booth: C65, Hall W8

Exhibition Highlights

1. MPLA Family: Precision-Engineered Immune Activation

For the first time, GC Biotech will present its full synthetic biology–based Monophosphoryl Lipid A (MPLA) product line, designed for advanced immune modulation:

• Tetra-acyl MPLA: TLR4-biased immune activation
• Penta-acyl MPLA: Enhanced neutralizing antibody response
• Hexa-acyl MPLA: Improved cellular immune performance

This product family represents a new level of precision in vaccine adjuvant design.

2. Plant-Derived Saponin Adjuvants

GC Biotech will also showcase its advanced Quillaja saponaria–derived saponin platform:

• QS-21: One of the most widely recognized plant-derived adjuvants, offering strong cost-performance advantages
• QS-7: Improved formulation with 40% reduced toxicity and 3× increased stability
• QS-10: A newly patented saponin fraction with enhanced synergistic immune activity

These plant-based adjuvants offer powerful tools for next-generation vaccine development, combining safety, stability, and efficacy.

Conclusion

The two upcoming exhibitions represent important milestones for innovation in both veterinary and human vaccine development.

GC Biotech looks forward to engaging with global partners, sharing advanced adjuvant technologies, and exploring new opportunities for collaboration across the biopharmaceutical industry.

We warmly welcome all industry professionals to visit our booths and join us in shaping the future of vaccine science.

https://en.jicangbio.com/gc-biotech-s-june-roadshow-veterinary-adjuvant-innovation-human-vaccine-breakthrough.html